Growth Metrics

Emergent BioSolutions (EBS) Long-Term Deferred Tax (2016 - 2020)

Emergent BioSolutions has reported Long-Term Deferred Tax over the past 11 years, most recently at $17.6 million for Q1 2020.

  • For Q1 2020, Long-Term Deferred Tax changed N/A year-over-year to $17.6 million; the TTM value through Mar 2020 reached $17.6 million, changed N/A, while the annual FY2019 figure was $13.4 million, 0.0% changed from the prior year.
  • Long-Term Deferred Tax for Q1 2020 was $17.6 million at Emergent BioSolutions, up from $13.4 million in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $18.2 million in Q2 2016 and troughed at $2.8 million in Q4 2017.
  • A 5-year average of $10.5 million and a median of $12.0 million in 2016 define the central range for Long-Term Deferred Tax.
  • Biggest five-year swings in Long-Term Deferred Tax: plummeted 72.39% in 2017 and later surged 378.57% in 2018.
  • Year by year, Long-Term Deferred Tax stood at $6.1 million in 2016, then plummeted by 54.07% to $2.8 million in 2017, then surged by 378.57% to $13.4 million in 2018, then changed by 0.0% to $13.4 million in 2019, then surged by 31.34% to $17.6 million in 2020.
  • Business Quant data shows Long-Term Deferred Tax for EBS at $17.6 million in Q1 2020, $13.4 million in Q4 2019, and $13.4 million in Q4 2018.